Finance

Lists
Why is ZNTL up १०.३२%?
Dive Deeper
ZNTL:NASDAQ
Zentalis Pharmaceuticals Inc
US$ २.७८
+१०.३२%
(+०.२६) 1D
US$ २.७९
+०.२४% (+०.००६७)
After hours
Closed: अक्टोबर ५, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZNTL...
Open
US$ २.६९
High
US$ २.८४
Low
US$ २.६३
Mkt. cap
२६.३२ करोड
Avg. vol.
११.०८ लाख
Volume
०.००
52-wk high
US$ ६.९५
52-wk low
US$ १.२१
EPS
-US$ १.९६
Beta
१.९३
Shares outstanding
९.४७ करोड
No. of employees
१०६
Open
US$ २.६९
High
US$ २.८४
Low
US$ २.६३
Mkt. cap
२६.३२ करोड
Avg. vol.
११.०८ लाख
Volume
०.००
52-wk high
US$ ६.९५
52-wk low
US$ १.२१
EPS
-US$ १.९६
Beta
१.९३
Shares outstanding
९.४७ करोड
No. of employees
१०६
News stories
From web sources and news partners
marketscreener.com
marketscreener.com
·
१२ घण्टा पहिले
Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
GuruFocus
GuruFocus
·
१७ घण्टा पहिले
ZNTL Assumed by Leerink Partners -- Price Target Raised to $8.00
AD HOC NEWS
AD HOC NEWS
·
१८ घण्टा पहिले
Zentalis Pharmaceuticals stock heads toward October cancer data
About Zentalis Pharmaceuticals Inc
CEO-
Employees१०६
Founded२०१४
Headquarters-
Sector-
Analyst ratings
Based on 8 analysts giving stock ratings to ZNTL in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ZNTL in the last 3 months.
Highest
Current US$ २.७८
US$ ११.०० (+२९५.६८%)
Average
US$ ८.१४ (+१९२.८१%)
Lowest
US$ ५.०० (+७९.८६%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Upgraded
US$ ८.००
+१८७.८%
10/05/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
US$ ५.००
+७९.९%
09/29/2026
Matt Phipps
William Blair
Buy
Initiated
-
-
09/15/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
US$ ८.००
+१८७.८%
08/11/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
US$ ५.००
+७९.९%
08/07/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
US$ १०.००
+२५९.७%
08/07/2026
Michael Schmidt
Guggenheim
Buy
Maintained
US$ १०.००
+२५९.७%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
US$ ११.००
+२९५.७%
07/23/2026
Jay Olson
Oppenheimer
Buy
Initiated
US$ ९.००
+२२३.७%
06/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
US$ ४.००
+४३.९%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$ ९.००
+२२३.७%
05/13/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
US$ ५.००
+७९.९%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
२.३० करोड
३.०७ करोड
२.८७ करोड
३.५२ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.०८ करोड
३७.६९ लाख
९१.३९ लाख
९२.२८ लाख
Operating expense
३.३७ करोड
३.४५ करोड
३.७९ करोड
४.४४ करोड
Total operating expenses
३.३७ करोड
३.४५ करोड
३.७९ करोड
४.४४ करोड
Operating income
-३.३७ करोड
-३.४५ करोड
-३.७९ करोड
-४.४४ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-२.६७ करोड
-३.४८ करोड
-३.५२ करोड
-४.२१ करोड
EBT excluding unusual items
-२.६७ करोड
-३.४१ करोड
-३.५२ करोड
-४.२१ करोड
Income tax expense
-
४.४२ लाख
१.२० लाख
१.३८ लाख
Effective tax rate
-
-१.२७%
-०.३४%
-०.३३%
Other operating expenses
-
-
-
-
Net income
-२.६७ करोड
-३.५२ करोड
-३.५४ करोड
-४.२३ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.३७
-०.४९
-०.५०
-०.५९
Interest and investment income
७०.४३ लाख
३.३८ लाख
२६.२३ लाख
२२.४३ लाख
Interest expense
-
-
-
-
Net interest expenses
७०.४३ लाख
३.३८ लाख
२६.२३ लाख
२२.४३ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.३६ करोड
-३.४३ करोड
-३.७७ करोड
-४.४२ करोड
Gain or loss from assets sale
-१.०३ लाख
-२६.०० हजार
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू